EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

Description

This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.

Conditions

Pancreatic Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.

Phase I Pilot Study of Endoscopic Ultrasound Guided RFA in Advanced Pancreatic Cancer

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

Condition
Pancreatic Cancer
Intervention / Treatment

-

Contacts and Locations

New York

Tisch Hospital, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosed and histologically confirmed PDAC by biopsy
  • * Axial CT scan or MRI consistent with PDAC with at least 1 cm in greatest diameter
  • * ECOG performance status 0-2
  • * Patients with locally advanced PDAC, who have not responded or progressed on first line chemotherapy, are deemed not resectable based on multidisciplinary review, and show no evidence of distant metastasis
  • * Lesions between 1 - 4cm in size
  • * Patients that show evidence of distant metastasis
  • * Endoscopically non-accessible mass
  • * Pregnant patients
  • * Inability to provide informed consent
  • * Lesions \<1cm, or \>4cm in greatest diameter

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NYU Langone Health,

Tamas A. Gonda, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

2026-03